RE: BNC launch of UrocidinSprules ...some excellent investigative work. Very helpful in better understanding the two competitive treatments outlined in the summary of the report. And indirectly, the (potential) value of Urocidin. I followed your links but only skimmed info. Two quick findings of interest I thought I would hilite from one of your links and going to Spectrum's website:
1) In December 2009, Spectrum Pharmaceuticals licensed to Nippon Kayaku exclusive rights to apaziquone for the treatment of non-muscle invasive bladder cancer in Asia, including Japan and China, for an upfront licensing fee of $15 million, plus up to $136 million in milestones, and royalties. Nippon Kayaku will conduct the apaziquone clinical trials pursuant to a development plan. Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of apaziquone in the Nippon Kayaku territory.
-->Spectrum's deal is much better than Bioniche's (Endo = global rights) but Spectrum in a different league to negotiate (albeit, what a rollercoaster this company has been on). If Urocidin's Ph111a results are as positive as many on this board suspect...it will be very, very interesting. Without a mention on the J.P. Morgan's HC Conf Call that the Ph111b had started recruiting in December, I really believe Endo is keeping a good thing "under wraps". Bottomline, MCC technology possibly worth much more than the $500 million in Endo's current M&A target account avail as mentioned on board. (I know I am now rambling, sorry for that)
2) Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer May 2010 08:31
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.
--> this other competitor (second of 2) is years behind in the development process.
When the world wakes up to Urocidin (assuming solid Ph111a results)...maybe McRae's $20sp for the company is very much inline in 1-2 years.
Tired and rambling but had to add the above and related thoughts to the work you started. Appreciate your time and effort spent on your diggings and findings. Very valuable!
rg